Epidermal growth factor receptor as a target: Recent developments in the search for effective new anti-cancer agents

Current Drug Targets

Volumn 2, Issue 2, 2001, Pages 117-133

  Seymour, L K ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 BROMOANILINO) 6 (METHYLAMINO)PYRIDO[3,4 D]PYRIMIDINE; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CETUXIMAB; CGP 59326; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IRINOTECAN; MATUZUMAB; MDX 447; MONOCLONAL ANTIBODY; NAVELBINE; NIMOTUZUMAB; OXALIPLATIN; PACLITAXEL; PLACEBO; RALTITREXED; TOPOTECAN; UNCLASSIFIED DRUG;

ADVANCED CANCER; ALLERGY; ANAPHYLAXIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG TARGETING; DYSPNEA; EPIGLOTTITIS; FEVER; GASTROINTESTINAL SYMPTOM; HEAD AND NECK CARCINOMA; HUMAN; HYPOTENSION; LUNG NON SMALL CELL CANCER; NAUSEA AND VOMITING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; RASH; SIGNAL TRANSDUCTION; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOGENICITY TESTS; GENE EXPRESSION; HUMANS; PROTEIN CONFORMATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 0034987273     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/1389450013348722     Document Type: Article

References (108)

1. The epidermal growth factor (EGF)
2. Epidermal growth factor induces rapid reversible aggregation of the purified epidermal growth factor receptor
3. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A341 epidermoid carcinoma cells
4. Epidermal growth factor related peptides and their receptors in human malignancies
5. Neu and its ligands: From an oncogene to a neural factor
6. EGF induces increased ligand binding affinity and dimerization of soluble epidermal growth factor (EGF) receptor extracellular domain
7. Molecules in focus: EGF receptor
8. Epidermal growth factor receptors: Critical mediators of multiple receptor pathways
9. Elevation of the epidermal growth factor receptor and dependent signaling in human papillomavirus-infected laryngeal papillomas
10. Epidermal growth factor receptor and EGF-R mutations.; function and possible role in clinical trials
11. Relationship between EGF-R.; c-erb-B-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity
12. Elevated levels of transforming growth factor α and epidermal growth factor messenger RNA are early markers of carcinogenesis in head and neck cancer
13. Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells
14. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas
15. Structure function and transforming potential of the epidermal growth factor receptor
16. Hyperproduction and gene amplification of the epidermal growth factor receptor in squamous cell carcinomas
17. Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification
18. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signalling
19. A deletion mutation within the ligand binding domain is responsible for activation of epidermal growth factor receptor gene in human brain tumours
20. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumours
21. Monoclonal antibodies against EGFRvIII are tumour specific and react with breast and lung carcinomas and malignant gliomas
22. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumourigenicity
23. A common mutant epidermal growth factor receptor confers enhanced tumourigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis
24. Drug resistance of human glioblastoma cells conferred by a tumour-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases
25. Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors
26. Epidermal growth factor protects epithelial cells against Fas induced apoptosis. Requirement for Akt activation
27. Epidermal growth factor.; but not hepatocyte growth factor.; suppresses the apoptosis induced by transforming growth factor-beta in fetal hepatocytes in primary culture
28. The EGFR and its inhibition in cancer
29. EGFR and TGF-α are potent chemoattractants for endothelial cells and EGFR-like peptides are present at sites of tissue regeneration
30. Epidermal growth factor promotes MDA-MB-231 breast cancer cell migration through a phosphatidylinositol 2′-kinase ad phospholipase C dependent mechanism
31. Evidence for a role of EGF receptor in the progression of human lung carcinoma
32. Evidence of autocrine mechanism in poorly differentiated adenocarcinoma of the stomach
33. Epidermal growth factor receptor and labelling index are independent prognostic factors in glial tumour outcome
34. Prognostic significance of epidermal growth factor receptor in laryngeal squamous carcinoma
35. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival
36. Expression of epidermal growth factor receptors is associated with lack of response to endocrine therapy in recurrent breast cancer
37. Potential indicators of radiosensitivity in squamous carcinoma of the head and neck
38. Oncoprotein (c-myc.; c-erb-B1.; c-fos) and suppressor gene product (p53) in squamous cell carcinomas of the lung. Clinical and biologic correlations
39. The expression of EGF receptors.; EGF-like factors and c-myc in ovarian and cervical carcinomas and their potential clinical significance
40. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival
41. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors.; oncoprotein (c-erb-B2.; p53) expression and long term prognosis
42. Epidermal growth factor receptor: An independent predictor of survival in astrocytic tumours given definitive irradiation
43. Further evidence for prognostic significance of epidermal growth receptor gene amplification in patients with esophageal squamous carcinoma
44. A phase I study of chimerized anti-epidermal growth factor receptor monoclonal antibody.; C225 in combination with cisplatin in patients with recurrent head and neck squamous cell carcinoma
45. Phase II study of anti-epidermal growth factor receptor antibody C225 alone in patients with metastatic renal cell carcinoma
46. Overall survival advantage to simultaneous chemotherapy plus the humanized anti-HER2 monoclonal antibody herceptin in HER-2 overexpressing metastatic breast cancer
47. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225
48. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: Progression from reversible to irreversible inhibitors
49. ZD1839.; an epidermal growth factor tyrosine kinase inhibitor selected for clinical development
50. Oral administration of the specific EGFR tyrosine kinase inhibitor ZD1839 (Iressa) is active against EGFR expressing intracranial tumors
51. Inhibition of growth factor production and angiogenesis in human cancer cell lines by ZD1839 (Iressa).; an EGFR-selective tyrosine kinase inhibitor
52. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa).; an epidermal growth factor receptor-selective tyrosine kinase inhibitor
53. ZD1839 (Iressa).; and EGFR TKI.; potentiates radiation/chemotherapy cytotoxicity in human non-small cell lung cancer (NSCLC) cell lines
54. Synergistic antitumour activity if IFN-α in HNSCC and melanoma cell lines
55. ZD1939 (Iressa).; and EGFR TKI.; and cisplatin have an additive effect on programmed cell death in human head and neck squamous carcinoma cells in vitro
56. An evaluation of the EGFR tyrosine kinase inhibitor ZD1839 (Iressa) in combination with ionising radiation
57. ZD1839 an oral epidermal growth factor receptor tyrosine kinase inhibitor: First phase I.; pharmacokinetic results in patients
58. A phase I intermittent dose-escalation trial of ZD1839 (Iressa) in Japanese pts with solid malignant tumours
59. Intermittent oral ZD1839 (Iressa).; a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) shows evidence of good tolerability and activity: Final results from a phase I study
60. Continuous administration of ZD1839 (Iressa) a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in patients with five selected tumour types: Evidence of activity and good tolerability
61. Pharmacodynamic effects of Iressa.; an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.; in skin biopsies from cancer patients participating in a phase I trial
62. Activated epidermal growth factor receptor: Studies in head and neck tumors and tumor cell lines after exposure to ligand and receptor tyrosine kinase inhibitors
63. A phase I.; dose escalation.; pharmacokinetics (PK) and pharmacodynamic (PD) study of ZD1839: NCIC CTG IND. 122
64. PD153035.; a tyrosine kinase inhibitor.; prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner
65. Apoptosis and growth inhibition of head and neck tumor cell line induced by epidermal growth factor receptor tyrosine kinase inhibitor
66. In vivo evaluation of the biodistribution of 11C-labeled PD153035 in rats without and with neuroblastoma implants
67. Induction of apoptosis and cell cycle arrest by CP358774.; an inhibitor of epidermal growth factor receptor tyrosine kinase
68. Inhibition of epidermal growth factor receptor associated tyrosine phosphorylation in human carcinomas with CP-358.;774: Dynamics of receptor inhibition in situ and antitumour effects in athymic mice
69. Investigation of the effects of CP-358.;774 (OSI-774) on various human tumor specimens taken directly from patients
70. Dose and schedule duration escalation of the epidermal growth factor receptor tyrosine kinase inhibitor CP358774: A phase I and pharmacokinetic study
71. Phase I dose escalation study of epidermal growth factor receptor tyrosine kinase inhibitor CP358774 in patients with advanced solid tumors
72. Phase 2 trial of single agent EGFR tyrosine kinase inhibitor (OSI-774) in non-small cell lung cancer following progression on platinum based chemotherapy
73. A phase II multicentre study of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).; OSI-774 (formerly known as CP-358774) in patients with advanced squamous cell carcinoma of the head and neck (SCCHN)
74. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies
75. Epidermal growth factor receptor blockade with C225 modulates proliferation.; apoptosis and radiosensitivity in squamous carcinomas of the head and neck
76. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model
77. Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice
78. Anti-EGF receptor monoclonal antibody IMC-C225 inhibits in-vitro and in vivo growth of non-small cell lung carcinoma
79. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice
80. The epidermal growth factor receptor (EGFr) as a therapeutic target in squamous cell malignancies
81. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody
82. Immunochemotherapy of human transitional cell carcinoma (TCC) with anti-EGF-R monoclonal antibody C225 and the anti-cancer drugs taxol and cisplatinum
83. Antitumour activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225
84. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms
85. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
86. Safety profile of the monoclonal antibody (MoAb) IMC-C225.; an anti-epidermal growth factor receptor (EGFr)-positive tumors
87. Low immunogenicity of a chimeric monoclonal antibody (MoAb).; IMC-C225.; used to treat epidermal growth factor receptor positive tumours
88. Monoclonal antibody (MoAb) IMC-C225.; an anti-epidermal growth factor receptor (EGFr) for patients with EGFr positive tumors refractory to or in relapse from previous therapeutic regimens
89. Continued response following treatment with IMC-C225.; an EGFr MoAb.; combined with RT in advanced head and neck malignancies
90. Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225
91. Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide
92. Detection of EGFR-positive circulating cancer cells in the blood of solid tumor patients
93. Development of angiogenesis inhibitors for cancer therapy
94. Phase I and II trials of novel anti-cancer agents: Endpoints.; efficacy and existentialism
95. A comparison of epidermal growth factor levels and other prognostic parameters in non-small cell lung cancer
96. Overexpression of epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in respectable non-small cell lung cancer but does not predict tumour progression
97. The clinical significance of epidermal growth factor receptor in human breast cancer: A review of 5232 patients
98. Expression of epidermal growth factor receptor mRNA and protein in primary breast cancers
99. Expression analysis of epidermal growth factor receptor and HER-2/neu: No advantage of prediction of recurrence or survival in breast cancer patients
100. Increased expression of the epidermal growth factor receptor on human colon carcinoma cells
101. Epidermal growth factor receptor gene amplification and expression in head and neck cancer cell lines
102. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck
103. The epidermal growth factor receptor in human pancreatic cancer
104. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R
105. A phase I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 in patients with solid tumors
106. Potent anti-tumor activity of ABX-EGF a fully human monoclonal antibody to the epidermal growth factor receptor
107. Therapeutic potential of ABX-EGF.; a fully human anti-EF receptor monoclonal antibody cancer treatment
108. Anti-epidermal growth factor receptor monoclonal antibodies for the induction of antibody-dependent cell mediated cytotoxicity against squamous cell carcinomas of the head and neck